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A B S T R A C T
Objectives: Differences between mometasone furoate (MF), administered once daily, and
fluticasone propionate (FP), administered twice daily, dosing regimens may affect adher-
ence and short-acting 2 agonist (SABA) use. The objective of this analysis was to compare
asthma control outcomes in matched cohorts of MF- and FP-treated asthma patients strat-
ified by SABA claims.
Methods: A retrospective pharmacy claimsdatabase analysis identifiedmatched cohorts of
asthma patients (aged 12–65 years) who initiated treatment with MF or FP. Patients with
none, one to four, five to eight, or more than eight SABA preindex claims were stratified to
categories A, B, C, andD, respectively. Bivariate analyses compared postindex SABA canister
claims, adherence, and exacerbations; multivariate analyses compared postindex SABA
canister claims.
Results: Matched patients in categories A (n  2517 per cohort) and B (n  2329 per cohort)
were analyzed; insufficient sample sizes were identified for categories C and D. Postindex
bivariate analyses indicated thatMF cohorts had fewer SABA claims compared to FP cohorts
(category A, 0.80 vs. 1.17 [P 0.0001]; category B, 1.39 vs. 1.58 [P 0.0001]), better adherence
to the index drug (category A, 24% vs. 15% [P 0.0001]; category B, 27% vs. 15% [P 0.0001]),
and fewer exacerbations (category A, 0.17 vs. 0.19 [P  0.011]; category B, 0.17 vs. 0.21 [P 
0.008]). Multivariate analyses indicated that MF cohorts had fewer postindex SABA claims
compared to FP cohorts in categories A and B (P  0.0001).
Conclusions: Data for SABA claims, treatment adherence, and exacerbations suggest that,
compared to twice-daily FP, once-daily MF may provide better asthma control.
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340 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 3 9 – 3 4 6Introduction
Current National Asthma Education and Prevention Program
(NAEPP) guidelines recommend low-dose inhaled corticoste-
roids (ICSs) as the preferred long-term treatment regimen for
patients with mild persistent asthma [1]. Two ICSs commonly
used for the treatment of asthma are mometasone furoate
(MF) and fluticasone propionate (FP). A critical component of
long-termasthma therapy is periodic evaluation andmonitor-
ing of asthma control for the occurrence of acute symptoms,
exacerbations, and exercise-induced bronchospasm requiring
the use of short-acting 2-agonists (SABA) as rescue medica-
tion [1]. Extensive use of SABAs is indicative of asthma that is
not well controlled and is also associated with an increased
risk of serious adverse events [2]. Current NAEPP guidelines
state that infrequent use (i.e., 2 days/week) of SABAs as res-
cue medication should be sought for optimizing asthma con-
trol [1]. As noted in current NAEPP guidelines [1], the use of
more than one SABA canister every month may suggest over-
reliance on SABA rescue medication and inadequate asthma
control [3] that is associated with an increased risk of hospi-
alization or emergency department visit [4–6]. In addition,
he mandatory conversion from chlorofluorocarbon to hydro-
uoroalkane propellants in SABA metered-dose aerosols has
dded significant cost to SABA medications [7], especially for
atients who use them frequently and/or inappropriately.
Meaningful differences in the overall asthma control pro-
ided by inhaled MF and FP have not been demonstrated in
linical studies [8,9]. Differences between the approved dosing
regimens of MF and FP, however, have the potential to affect
several important patient outcomes, including asthma control.
MF is approved for maintenance treatment of asthma using a
once-daily (QD) dosing regimen in all patients, except those 12
years of age and older taking oral corticosteroids, who should
beginMFtreatmentusinga twice-daily (BID)dosing regimen [10].
FP is only approved for BID administration [11]. Decreases in the
prescribed number of daily medication doses for most chronic
diseases [12], including asthma [13], are generally associated
with increased patient adherence. Proper patient adherence is
critical for optimizing asthma control [14], and current NAEPP
guidelines recommend that physicians regularly assess and en-
courage patient adherence to prescribed asthma medications
[1]. Furthermore, decreased SABA use has been associated with
high adherence to prescribed ICS therapy [13].
Given the important associations between ICS dosing fre-
quency, patient adherence, and SABA rescue medication use,
the objective of the current retrospective claims database
analysis was to compare SABA claims, ICS adherence, and
asthma exacerbation incidence among matched cohorts of
asthma patients who used either inhaled MF or inhaled FP.
Methods
Study design
Pharmacy claims between January 1, 2005, and September 30,
2008, from a commercial insurance database in the United eStates (Ingenix LabRx, Eden Prairie, MN) were analyzed retro-
spectively to identify patients with asthma who initiated
treatment with inhaled MF (Asmanex; Schering-Plough Corp.,
Kenilworth, NJ) or FP (Flovent, GlaxoSmithKline, Research Tri-
angle Park, NC); the date of the initial first MF or FP prescrip-
tion was defined as the index date for each individual patient.
During this time period, the database included approximately
37 million patients; the majority of patients resided in the
southern or midwestern United States (South, 43%; Midwest,
33%; West, 13%; Northeast, 11%).
Patients were assigned to one of four categories depending
on the number of SABA canister claims in the 365-day prein-
dex period: category A, no SABA canister claims; category B,
one to four SABA canister claims; category C, five to eight
SABA canister claims; category D, more than eight SABA can-
ister claims.
Assessments
Each cohort’smeannumbers of SABA claims, adherence toMF
or FP, mean numbers of asthma exacerbations, and asthma
exacerbation incidence were evaluated in the 365-day postin-
dex period. Adherencewas assessed bymeasuring percentage
of days covered (PDC) during the postindex period. Asthma
exacerbationswere defined as any asthma-related emergency
department treatment or hospitalization or an outpatient visit
during which patients received nebulization or a prescription
for oral corticosteroids, as previously described [15].
Statistical analyses
Patient selection was based on the following inclusion and
exclusion criteria: enrolled 1 year before and 1 year after
index date (defined as the preindex and postindex periods,
respectively); 12 to 65 years of age; diagnosed as having
asthma (i.e., was designated International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]
codes 493, 493.1, or 493.9); had no chronic pulmonary condi-
tion other than asthma (i.e., was not designated ICD-9-CM
codes 415, 416, 417, 491, 491.2, 492, 493.2, 494, or 770.2); re-
ceived no treatment with an ICS/long-acting 2 agonist (LABA)
ombination product within 7 days of index date; in the MF
ohort, received no FP within 7 days of the MF index date; in
he FP cohort, received no MF within 7 days of the FP index
ate; belonged in one and only one treatment cohort. Patient
emographic and descriptive statistics were compiled for all
atients who met these inclusion and exclusion criteria. A
ne-to-onematch of selected patients based on comorbidities,
emographics, and asthma resource claims was performed
sing a greedymatching algorithm [16]. Using a rough approx-
mation of normal distribution, it was estimated that sample
izes for all analyzed subgroups (i.e., SABA category subgroups
ithin treatment cohorts) were required to be 300 to gener-
te clinically relevant comparisons. Patient demographic and
escriptive statistics were compiled for all matched patients.
ivariate analyses were used to compare mean numbers of
ostindex SABA claims (Kruskal-Wallis test), adherence to MF
r FP (Kruskal-Wallis test), mean numbers of postindex exac-


























341V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 3 9 – 3 4 6cidence (chi-square test) between treatment groups. General-
ized linear models (GLMs) controlling for preindex patient
demographics, use patterns, and select patient comorbidities
and health outcomes (i.e., all demographic and characteristic
variables listed in Table 1) assuming Poisson distributionwere
lso used to compare the numbers of postindex SABA canister
laims andmean numbers of exacerbations. A GLM assuming
amma distribution was used to compare adherence between
roups. In addition to bivariate analysis, differences in postin-
ex exacerbation incidencewere analyzed by a logistic regres-
ion model. Because postindex SABA claims data are a type of
ount variable, Poisson distribution was assumed for GLM
nalyses. A previous retrospective claims database study also
sed multivariate GLM analyses with Poisson distribution
hen comparing postindex SABA claims among patients
tratified by preindex SABA claims [17].
Results
A total of 16,063 patients qualified for inclusion in these anal-
yses (Fig. 1). There were 3106, 2853, 342, and 256 MF patients
and 4795, 3973, 418, and 320 FP patients assigned to the prein-
dex SABA categories A, B, C, and D, respectively (Fig. 1). Not
enough MF patients in categories C or D were identified for
adequate patientmatching (i.e., matched patient sample sizes
within categories C and D were 300; data not shown); there-
fore, only patients in categories A and B were analyzed. For
each drug cohort, 2517 categoryApatients and 2329 category B
patients were matched for analysis.
Mean patient ages for both drug treatment cohorts in cat-
egories A and B ranged from 35.9 to 39.1 years, and the major-
ity of all patients were women (Table 1). There were no signif-
icant differences between MF and FP cohorts in comorbidity
prevalence, preindex asthma exacerbations, preindex SABA
canister claims, or patient demographics in category A or B




MF (n  2517) FP (n  25
Mean age, y 38.7 39.1




Acute bronchitis 17.3 15.7
Upper respiratory infection 17.5 18.2
GERD 10.3 10.4
Pneumonia 2.8 2.4
Acute nasopharyngitis 1.5 1.6
Acute laryngitis 1.4 1.6
Mean exacerbations, no. 0.12 0.12
Mean SABA claims, no. 0 0
FP, fluticasone propionate; GERD, gastroesophageal reflux disease; M
* No SABA canister claims during the preindex period.
† One to four SABA canister claims during the preindex period.(Table 1). sSABA claims in matched cohorts
Bivariate analyses indicated that significantly fewer patients
who received MF had postindex claims for SABA canisters
compared to those who received FP in categories A and B (cat-
egory A, 0.80 vs. 1.17, respectively [P 0.0001]; category B, 1.39
s. 1.58, respectively [P 0.0001]; Fig. 2). GLMs assuming Pois-
on distribution also indicated that MF treatment was associ-
ted with significantly fewer postindex SABA canister claims
ompared to FP treatment (P  0.0001; Table 2).
Using previously published cost estimates for SABAs ad-
inistered via aerosol inhalers with hydrofluoroalkane (HFA)
ropellants [18], the significant differences in postindex SABA
anister claims between patient treatment groups observed in
he current study suggest that patients withmild asthma (i.e.,
atients with four or fewer preindex SABA claims) receiving
F spend less annually on SABAs than patients with mild
sthma receiving FP (Table 3).
Adherence in matched cohorts
In categoriesAandB, bivariateanalysis indicatedadherence (de-
fined as PDC) was significantly better in the postindex period
among patients who received MF compared to those who re-
ceived FP (category A, PDC  24% vs. 15%, respectively [P 
0.0001]; category B, PDC 27% vs. 15%, respectively [P 0.0001];
ig. 3). GLM analysis confirmed these results (category A,  
.4553 [P 0.0001]; category B,  0.5704 [P 0.0001]) (Table 2).
Exacerbations in matched cohorts
According to bivariate analysis, patients who used MF experi-
enced significantly fewer mean asthma exacerbations in the
postindex period compared to thosewho used FP in categories
A and B (category A, 0.17 vs. 0.19, respectively [P  0.011];
category B, 0.17 vs. 0.21, respectively [P 0.008]; Fig. 4A). Using
LM analysis, only patients in category B who used MF had
Category B†
P value MF (n  2329) FP (n  2329) P value
0.244 35.9 36.0 0.968
0.130 60.8 62.3 0.306
0.977 46.6 47.4 0.577
0.658 31.8 31.0 0.570
0.119 25.8 24.9 0.479
0.532 23.0 23.0 1.000
0.963 10.5 9.4 0.222
0.374 5.7 6.7 0.129
0.910 1.8 1.8 1.000
0.488 1.5 1.4 0.712
0.706 0.24 0.25 0.147
1.000 1.65 1.66 0.842
metasone furoate; SABA, short-acting 2 agonist.17)






342 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 3 9 – 3 4 6index period compared to category B patients who used FP
(  0.1913 [P  0.005]) (Table 2). The directionality of the
coefficient for category A was consistent with the result in
Fig. 2 – SABA canister claims in matched cohorts. The
mean number of SABA canister claims among patients
treated with MF or FP during the postindex period are
depicted and compared using bivariate analyses for
categories A and B. Category A patients had no SABA
canister claims during the preindex period; category B
patients had one to four SABA canister claims during the
preindex period. Error bars represent standard error of the
mean. FP, fluticasone propionate; MF, mometasone
furoate; SABA, short-acting 2 agonist. *P < 0.0001 by
Fig. 1 – Patient selection. Patients were identified from a com
identify those with asthma who initiated treatment with inh
criteria were assigned to one of four categories depending o
fluticasone propionate; ICS, inhaled corticosteroid; MF, momivariate analysis.category B (i.e., fewer mean exacerbations for patients who
used MF), although statistical significance was not achieved
(  0.1039 [P  0.119]) (Table 2). Bivariate analysis indi-
ated that significantly fewer patients who used MF ever
ad an exacerbation in the postindex period compared to
hose who used FP in categories A and B (category A, 11% vs.
3%, respectively [P  0.008]; category B, 12% vs. 15%, re-
spectively [P  0.008]; Fig. 4B). The significance of these dif-
ferences in exacerbation incidence was confirmed by logis-
tic regression showing a risk reduction of approximately
20% for patients using MF versus FP in either category A
(odds ratio 0.795 [P  0.009]) or category B (odds ratio 0.803
[P  0.013]) (Table 2).
Discussion
Bivariate analyses indicated that asthma patients with four or
fewer preindex SABA claims who received MF treatment had
fewer postindex SABA claims and better adherence during the
postindex period than a matched cohort of patients using FP.
Patients who used MF also had fewer postindex SABA claims
and better adherence than FP patients when GLM analyses
were used, regardless of whether adjustments for patient ad-
herence were included. In addition, bivariate analyses indi-
rcial insurance database and analyzed retrospectively to
MF or FP. Patients who met all inclusion and exclusion
BA canisters claimed in the preindex period. FP,
one furoate; SABA, short-acting 2 agonist.me
aled
n SA





























343V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 3 9 – 3 4 6SABA claims were less likely to have an exacerbation and had
fewer mean exacerbations than FP-treated patients with four
or fewer preindex SABA claims. Differences in exacerbation
data were generally confirmed by GLM and logistic regression
analyses. Because both SABA rescue medication use and
asthma exacerbations are key components of asthma control
[1], it is not surprising that results concerning these two out-
comes paralleled one another. In previous studies, increased
SABA canister use [19] and asthma exacerbation rates [20]
ere associated with decreased asthma control. In one large
rospective study (N 2056), each increase in the daily use of
nebulized SABA corresponded with 6- and 20-fold increases
n the likelihood of an asthma-related emergency department
isit and hospitalization, respectively [21].
Fewer SABA claims, better adherence, and fewer exacerba-
ions with MF over FP may have resulted from unstudied MF
evice preferences or overall improved effectiveness of MF
herapy. It is likely that better adherence to MF treatment pri-
arily stemmed from the lower dosing frequency of MF com-
ared to FP (i.e., QD vs. BID, respectively). Although some pa-
ientswho receivedMFmayhave beenprescribed a BIDdosing
egimen if they had previously received oral corticosteroids, it
s likely the majority of patients who initiated MF treatment






SABA canisters 0.3702 0.4269 to 0.313
Adherence 0.4553 0.4151  0.4955
Mean exacerbations 0.1039 0.2345 to 0.0267
Exacerbation incidence 0.795 0.670  0.945
CI, confidence interval; SABA, short-acting 2 agonist.
* No SABA canister claims during the preindex period.
† One to four SABA canister claims during the preindex period.
‡ Values for SABA canisters, adherence, andmean exacerbations rep
odds ratios.
Table 3 – Estimated annual SABA HFA costs*.
Postindex SABA canister claims
SABA delivered via HFA
ProAir® (albuterol sulfate; Teva Specialty Pharmaceuticals,
Horsham, PA)
Proventil® (albuterol sulfate; Schering-Plough Corp.,
Kenilworth, NJ)
Ventolin® (albuterol sulfate; GlaxoSmithKline, Research
Triangle Park, NC)
Xopenex® (levalbuterol HCl; Sepracor, Marlborough, MA)
FP, fluticasone propionate; HFA, hydrofluoroalkane; MF, mometason
* Estimates calculated bymultiplyingmean postindex SABA claims fo
at the lowest recommended dose [18].
† No SABA canister claims during the preindex period.
‡ One to four SABA canister claims during the preindex period.ndhad four or fewer preindex SABA claims in this studywere
rescribed a QD dosing regimen. In a systematic review of
edication compliance across several therapeutic areas,
laxton et al. [12] found that mean compliance rates were
pproximately 28% higher for patients on a QD dosing regi-
en compared to those on a BID dosing regimen (74% vs. 58%,
espectively). A similar trendwas observed by Guest et al. [13],
ho found that asthma patients who switched from a BID ICS
o a QD ICS had significantly better adherence rates than pa-
ients who remained on a BID ICS. Optimizing adherence to
rescribed medications is critical for reducing chronic dis-
ase-related morbidity and mortality, particularly for asthma
atients who are estimated to have adherence rates of 50%
14,22]. In one study, prescribed ICS adherence was only 48.1%
weeks after hospitalization for an asthma exacerbation [23].
Not surprisingly, poor ICS adherence was associated with
significantly worse asthma symptom scores in this study
[23]. Current NAEPP guidelines recommend that physicians
regularly assess and encourage patient adherence to pre-
scribed asthmamedications [1]. Furthermore, NAEPP guide-
lines [1] also note that adherence to a written “asthma ac-
tion plan” is optimized when the frequency of daily dosing






95% CI P value
0.0001 0.1311 0.1785 to 0.0838 0.0001
0.0001 0.5704 0.5290  0.6118 0.0001
0.119 0.1913 0.3238 to 0.0587 0.005
0.009 0.803 0.675  0.955 0.013
t regression coefficients; values for exacerbation incidence represent
Category A† Category B‡
MF FP MF FP
0.80 1.17 1.39 1.58
Estimated annual SABA HFA cost, $
27.14 39.69 47.15 53.59
33.07 48.37 57.46 65.32
28.94 42.33 50.29 57.16
42.00 61.43 72.98 82.95
ate; SABA, short-acting 2 agonist.




a344 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 3 9 – 3 4 6mote increased adherence, such as QD MF, may provide
superior control of mild persistent asthma simply because
patients are more likely to self-administer all their pre-
scribed medication compared to ICSs that require more
than one daily dose.
Increased adherence to asthma therapy has previously
been associated with decreases in SABA rescue medication
use [13]. Although current NAEPP guidelines indicate that
SABAs are the most effective medication for relieving acute
bronchospasm, long-term use of SABAs is not recommended
and extensive use of SABAs as rescue medication (i.e., 2
days/week) indicates inadequate asthma control [1]. In one
large study (N  29,957) of asthma patients, more frequent
SABA use was associated with increased risk of asthma-re-
lated hospitalizations, regardless of asthma severity [27]. Pa-
tients included in the current analysis had claims for 0 to 4
canisters during the preindex period and would not be char-
acterized as frequent SABA users. For asthma patients pre-
scribed ICS monotherapy such as MF or FP, minimal rescue
medication use is desirable, and significant reductions in the
use of SABA rescue medication may indicate better asthma
control. It is important to note that the current study did not
assess all aspects of asthma control, and further prospective
clinical trials are necessary to confirm whether MF provides
better asthma control than FP. For example, current NAEPP
guidelines indicate that the prevention of troublesome
asthma symptoms, maintenance of normal pulmonary func-
tion, and patient satisfaction are also important components
of asthma control [1]; these and other asthma control-related
variables were not assessed in the current study due to the
nature of retrospective database analyses. All important
asthma control measures that can be assessed in this type of
retrospective study were explored. NAEPP guidelines indicate
Fig. 3 – Adherence in matched cohorts. Adherence (defined
as PDC) among patients treated with MF or FP during the
postindex period are depicted and compared using
bivariate analyses for categories A and B. Category A
patients had no SABA canister claims during the preindex
period; category B patients had one to four SABA canister
claims during the preindex period. Error bars represent
standard error of the mean. FP, fluticasone propionate; MF,
mometasone furoate; PDC, percentage of days covered;
SABA, short-acting 2 agonist. *P < 0.0001 by bivariate
nalysis.that infrequent use of SABAs and the prevention of recurrent 0asthma exacerbations are components of asthma control. As
such, we believe the current data suggest thatMFmay provide
better asthma control than FP. Furthermore, other studies
have significantly correlated improved adherence to asthma
therapy with positive asthma-related outcomes, including re-
duced exacerbations [28], improved asthma control scores
[23,29], and reduced emergency department visits [30]. Collec-
tively, these data suggest that the improved asthma-related
outcomes observed in the current study may have been re-
lated to the significantly better adherence among patients
who used MF compared to those who used FP.
In addition, reductions in SABA use provide noticeable cost
savings to patients who previously used SABA inhalers with
chlorofluorocarbon propellants and now must use more ex-
pensive SABA aerosol inhalers with HFA propellants [31]. The
estimated annual SABAHFA cost data depicted in Table 2were
not analyzed statistically and are notmeant to be robust com-
parisons of SABA cost data between patients who used MF or
FP in the current study. These data, however, underscore the
Fig. 4 – Exacerbations in matched cohorts. The mean
number of postindex exacerbations (A) and the
percentages of patients who experienced an exacerbation
during the postindex period (B) among patients treated
with MF or FP are depicted and compared using bivariate
analyses for categories A and B. Category A patients had
no SABA canister claims during the preindex period;
category B patients had one to four SABA canister claims
during the preindex period. Error bars in 4A represent
standard error of the mean. FP, fluticasone propionate; MF,
mometasone furoate; SABA, short-acting 2 agonist. *P =

































345V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 3 3 9 – 3 4 6simple fact that reducing SABA use can lower asthma-related
health-care charges, which is important for a disease with a
high global economic burden such as asthma [32]. Further
studies would be necessary to directly compare SABA costs
among patients who us MF or FP in a statistically meaningful
and clinically relevant manner.
The inability to generate data from a sufficient number of
patients who used five ormore SABA canisters during the pre-
index period was a limitation of this study. This limitation is
not surprising because themajority of asthma patients have a
form of the disease that does not require extensive rescue
medication use. The Epidemiology and Natural History of
Asthma: Outcomes and Treatment Regimens (TENOR) study
(N  2927) showed that among patients who were character-
zed by their physician as having severe or difficult-to-treat
sthma, symptom scores suggested that most patients actu-
lly had mild asthma [33], which likely would not have re-
uired as much rescue medication as patients with more se-
ere forms of the disease. Furthermore, it is likely that many
atients who would have used five or more SABA canisters in
he preindex period received treatment with an ICS/LABA
ombination product in the 7 days before the index date,
hichwas an exclusion criterion of the current study. Because
AEPP guidelines indicate low-dose ICS monotherapy as the
referred treatment regimen for mild persistent asthma [1],
his was the most important form of asthma to be considered
n this analysis of two ICS monotherapy products, and it is
ikely that mild persistent asthma patients would not require
ve or more SABA canisters per year.
Because thiswas a claims analysis, a limitation of the study
as the lack of clinical information about the patients; further
rospective clinical trials using amore complete set of asthma
ontrol outcome measures would be necessary to confirm
hetherMF provides superior asthma control compared to FP.
lthough more clinical information would have been helpful
n interpreting these data, this type of retrospective analysis
ay more closely represent a real-life setting than a formal
linical trial. Furthermore, this limitation is inherent to all
laims database analyses and does not preclude the develop-
ent of clinically relevant conclusions from these data.
Conclusions
Following current NAEPP guidelines to minimize SABA use
and promote adherence to controller therapy is critical for
successfully managing persistent asthma. Collectively, SABA
claims, treatment adherence, and asthma-related exacerba-
tion data suggest that MF may provide better control of
asthma than FP among patients who require limited SABA
rescue medication.
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